Cargando…

Bcl-2 antagonists and cancer: from the clinic, back to the bench

Detalles Bibliográficos
Autor principal: Esposti, M Degli
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032303/
https://www.ncbi.nlm.nih.gov/pubmed/21364644
http://dx.doi.org/10.1038/cddis.2010.15
_version_ 1782197444013981696
author Esposti, M Degli
author_facet Esposti, M Degli
author_sort Esposti, M Degli
collection PubMed
description
format Text
id pubmed-3032303
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-30323032011-02-24 Bcl-2 antagonists and cancer: from the clinic, back to the bench Esposti, M Degli Cell Death Dis Meeting Report Nature Publishing Group 2010-04 2010-04-29 /pmc/articles/PMC3032303/ /pubmed/21364644 http://dx.doi.org/10.1038/cddis.2010.15 Text en Copyright © 2010 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 license. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Meeting Report
Esposti, M Degli
Bcl-2 antagonists and cancer: from the clinic, back to the bench
title Bcl-2 antagonists and cancer: from the clinic, back to the bench
title_full Bcl-2 antagonists and cancer: from the clinic, back to the bench
title_fullStr Bcl-2 antagonists and cancer: from the clinic, back to the bench
title_full_unstemmed Bcl-2 antagonists and cancer: from the clinic, back to the bench
title_short Bcl-2 antagonists and cancer: from the clinic, back to the bench
title_sort bcl-2 antagonists and cancer: from the clinic, back to the bench
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032303/
https://www.ncbi.nlm.nih.gov/pubmed/21364644
http://dx.doi.org/10.1038/cddis.2010.15
work_keys_str_mv AT espostimdegli bcl2antagonistsandcancerfromtheclinicbacktothebench